Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)3.43
  • Today's Change-0.05 / -1.44%
  • Shares traded1.15m
  • 1 Year change13.58%
  • Beta0.6857
Data delayed at least 15 minutes, as of Dec 12 2019 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

  • Revenue in USD (TTM)105.67m
  • Net income in USD756.00k
  • Incorporated1986
  • Employees87.00
  • Location
    PDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
  • Phone+1 (775) 832-8500
  • Fax+1 (775) 832-8501
  • Websitehttp://www.pdl.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Recro Pharma Inc99.36m-50.42m378.46m255.00------3.81-2.33-2.334.51-0.87850.57874.474.31389,643.10-29.37-27.24-35.74-32.5048.02---50.74-61.086.79-0.59241.22--7.67---89.01------
SIGA Technologies, Inc.24.05m49.65m378.62m41.007.533.687.5615.740.62020.62020.29431.270.13870.513310.11586,520.0028.644.4730.124.6992.70--206.487.428.03-0.34330.4341--3,788.30143.971,183.35---34.64--
Rigel Pharmaceuticals, Inc.81.75m-46.47m382.15m160.00--5.55--4.67-0.2777-0.27770.4890.41110.58551.0711.03517,373.40-33.28-54.09-40.67-64.5398.88---56.84-338.024.03--0.1244--892.6244.159.63---1.96--
Evolus Inc15.48m-87.97m392.36m228.00--19.34--25.35-3.21-3.210.56510.62140.0846--4.30221,114.30-48.06---52.58--71.71---568.34--3.28-23.360.842-------3,622.56------
Stealth BioTherapeutics Corp0.00-102.05m393.37m57.00--104.66-----2.96-2.960.000.10730.00----0.00-398.48-----------------8.500.8201-------16.65------
OptiNose Inc26.57m-111.44m393.78m99.00--8.83--14.82-2.70-2.700.6431.070.13730.68943.77268,414.20-57.59---66.60--85.20---419.37--4.66-14.080.6252-------72.12------
Milestone Pharmaceuticals Inc0.00-46.66m396.81m23.00--2.99-----1.95-1.950.005.42------0.00--------------------0.00-------186.73------
PDL BioPharma Inc105.67m756.00k397.36m87.00--0.623458.973.76-0.0278-0.02780.84225.580.11433.096.631,006,391.000.04514.680.047217.2851.14--0.393739.369.43--0.172127.81-38.10-15.37-161.78---36.70--
Arcus Biosciences Inc6.81m-80.41m404.02m108.00--2.28--59.31-2.79-2.790.1933.870.027--1.3363,074.07-31.93---34.51-------1,180.37------0.00--491.15--6.57------
Tcr2 Therapeutics Inc0.00-96.09m404.97m71.00--2.36-----3.98-3.980.007.150.00----0.00-27.03---28.07--------------0.00-------314.08------
Avid Bioservices Inc64.40m-9.55m409.58m211.00--8.33--6.36-0.1699-0.16811.150.8730.69456.195.65305,227.50-4.85-14.06-7.00-24.7815.7523.84-6.99-30.081.44--0.00---0.033619.0761.42--14.75--
AnaptysBio Inc5.00m-94.07m411.61m78.00--0.9767--82.32-3.49-3.490.185415.530.0103--1.9364,102.56-19.30-13.42-20.36-14.43-----1,881.34-150.34----0.0073---50.00-1.83-105.04--95.73--
Fast Line Holding Inc0.00-342.94k411.93m-----------0.0033-0.00330.00-0.00230.00-------68.89---380.60-------------2,906.582.83------89.79------
Beyondspring Inc0.00-43.69m415.29m52.00---------1.90-1.900.00-0.68830.00----0.00-292.33---1,045.47-------------122.46--------40.21------
Gritstone Oncology Inc4.57m-84.07m415.71m164.00--2.65--90.93-2.61-2.610.1434.380.0284----40,460.18-52.24---58.95-------1,838.76------0.00-------56.55------
Data as of Dec 12 2019. Currency figures normalised to PDL BioPharma Inc's reporting currency: US Dollar USD

Institutional shareholders

55.41%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 30 Sep 201910.21m8.94%
BlackRock Fund Advisorsas of 30 Sep 201910.19m8.93%
Renaissance Technologies LLCas of 30 Sep 20199.36m8.20%
The Vanguard Group, Inc.as of 30 Sep 20196.06m5.31%
Engine Capital Management LPas of 21 Oct 20196.03m5.28%
Brandes Investment Partners LPas of 30 Sep 20195.47m4.79%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 20194.48m3.92%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Sep 20194.39m3.84%
Charles Schwab Investment Management, Inc.as of 30 Sep 20193.67m3.22%
SSgA Funds Management, Inc.as of 30 Sep 20193.40m2.98%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.